

Emerging Markets, such as South Africa, represent an interesting environment for biologics, and biosimilars in particular. With an established regulatory approval process, payer and prescriber acceptance of biosimilars, a growing population and unmet medical needs, South Africa offers an ideal environment for biosimilars to increase their global footprint.
Our whitepaper examines the impact of biologics and biosimilars in South Africa, including their uptake and their potential.